This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
by Zacks Equity Research
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
by Zacks Equity Research
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
by Zacks Equity Research
RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.
Top Analyst Reports for Coca-Cola, Abbott & RTX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Co. (KO), Abbott Laboratories (ABT) and RTX Corp. (RTX), as well as two micro-cap stocks Investors Title Co. (ITIC) and Armanino Foods of Distinction, Inc. (AMNF).
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
by Kinjel Shah
JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies
by Zacks Equity Research
Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
by Zacks Equity Research
The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
by Zacks Equity Research
Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in after-hours trading.
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
by Zacks Equity Research
The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
by Zacks Equity Research
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries
by Zacks Equity Research
Roche Holding, Comcast, Eaton Corp and National Presto Industries are included in this Analyst Blog.
Top Analyst Reports for Roche, Comcast & Eaton
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp. (CMCSA) and Eaton Corp. plc (ETN), as well as two micro-cap stocks National Presto Industries, Inc. (NPK) and Cemtrex, Inc. (CETX).
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
by Sundeep Ganoria
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
by Zacks Equity Research
Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.
Novartis Reports Updated Positive Data From Phase III SMA Program
by Zacks Equity Research
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
by Zacks Equity Research
Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
by Zacks Equity Research
Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
by Zacks Equity Research
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
by Zacks Equity Research
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
by Zacks Equity Research
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
by Kinjel Shah
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.